Validating biomarkers of treatable mechanisms in irritable bowel syndrome
Validating biomarkers of treatable mechanisms in irritable bowel syndrome
复制标题
DOI：
10.1111/nmo.12421
复制
发表时间：
2014-12-01
影响因子：
3.5
通讯作者：
Zinsmeister, A. R.
中科院分区：
文献类型：
--
作者：
Camilleri, M.;Shin, A.;Zinsmeister, A. R.
“有效的生物标志物是正常的生物或致病过程，或对治疗干预的药理学反应的指标”。肠易激综合征（IBS）没有有效的生物标志物。该研究的目的是评估三个定量特征识别可治疗过程的能力，以区分ibs -腹泻（IBS-D）患者、ibs -便秘（IBS-C）患者和健康志愿者（HV）。方法对30例HV、30例IBS-C和64例IBS-D患者进行肠道症状表征和病理生理机制定量分析：胆汁酸（BA）合成（血清C4和FGF19）、粪便BA和脂肪、结肠运输（CT）和肠通透性（IP）。我们使用多元逻辑回归和接受者操作特征（ROCAUC）来单独和联合评估三个因素（粪便BA、CT和IP），以确定IBS治疗的鉴别靶点。关键结果三个亚组与反映肠道功能的症状和数量性状之间存在显著相关性。48h时粪便BA与CT有显著相关性(r=0.43
BackgroundA valid biomarker is an indicator of normal biologic or pathogenic processes, or pharmacological responses to a therapeutic intervention'. There is no validated biomarker for irritable bowel syndrome (IBS). The aim of the study was to assess ability of three quantitative traits to identify treatable processes to discriminate between IBS-diarrhea (IBS-D) patients, IBS-constipation (IBS-C) patients and healthy volunteers (HV).MethodsIn 30 HV, 30 IBS-C patients and 64 IBS-D patients, we characterized bowel symptoms and quantitated pathophysiological mechanisms: bile acid (BA) synthesis (serum C4 and FGF19), fecal BA and fat, colonic transit (CT), and intestinal permeability (IP). We used multiple logistic regression and receiver-operating characteristic (ROCAUC) to appraise three factors (fecal BA, CT, and IP) individually and in combination to identify discriminant targets for treatment in IBS.Key ResultsThere were significant associations between the three subgroups and symptoms reflecting bowel function and the quantitative traits. There were significant associations between fecal BA and CT at 48h (r=0.43; p